Intellia Therapeutics (NTLA) Current Leases (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Current Leases data on file, last reported at $19.1 million in Q1 2026.

• Quarterly Current Leases fell 50.74% year-over-year to $19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.1 million (down 50.74% YoY) and the FY2025 annual result came in at $26.5 million, up 30.79% from the prior year.
• Current Leases slipped to $19.1 million in Q1 2026 per NTLA's latest filing, from $26.5 million in the prior quarter.
• Across five years, Current Leases topped out at $38.8 million in Q1 2025 and bottomed at $9.3 million in Q1 2022.
• The 5-year median for Current Leases is $18.8 million (2024), against an average of $19.6 million.
• The widest annual swing landed in 2025, when Current Leases soared 106.59%; it then slumped 50.74% in 2026.
• Tracing NTLA's Current Leases over 5 years: stood at $16.7 million in 2022, then grew by 11.47% to $18.6 million in 2023, then rose by 8.86% to $20.2 million in 2024, then jumped by 30.79% to $26.5 million in 2025, then fell by 27.89% to $19.1 million in 2026.
• Per Business Quant, the three latest NTLA Current Leases figures stand at $19.1 million (Q1 2026), $26.5 million (Q4 2025), and $27.4 million (Q3 2025).

Peer Comparison